"We are thrilled to once again collaborate with
“We are excited to offer patients with ER+ HER2- advanced breast cancer the opportunity to incorporate TK testing with the goal of further tailoring treatment, reducing unnecessary toxicity and improving patient outcomes,” says
The BettER study seeks to evaluate the impact of early therapeutic switching based on biomarker-driven insights, utilizing DiviTum TKa to guide treatment decisions. The study will enroll 50 patients, assessing the effectiveness of modifying treatment based on TKa levels measured at baseline and shortly after treatment initiation. Patients demonstrating insufficient TKa suppression will be recommended for an alternative therapy, potentially enhancing treatment outcomes.
© Modular Finance, source